Table 1.
Serum levels of pro‐inflammatory mediators in all treatment groups
| WT | ApoE−/− | ApoE−/− + CTS‐15 | ApoE−/− + CTS‐45 | |
|---|---|---|---|---|
| IL‐1β (pg mL−1) | 49.6 ± 5.1 | 286.6 ± 13.3 ### | 212.6 ± 10.6** | 109.3 ± 6.9*** |
| IL‐6 (pg mL−1) | 5.4 ± 0.1 | 47.1 ± 2.5 ### | 27.9 ± 1.2*** | 12.8 ± 0.7*** |
| IL‐17A (pg mL−1) | 86.7 ± 5.2 | 288.3 ± 11.6 ### | 222.3 ± 9.9* | 140.5 ± 6.3*** |
| IFN‐γ (pg mL−1) | 18.2 ± 0.1 | 31.3 ± 1.8 ## | 23.9 ± 1.2* | 19.5 ± 1.0** |
| TNF‐α (pg mL−1) | 157.5 ± 7.5 | 443.8 ± 18.4 ### | 412.3 ± 22.1 | 238.0 ± 12.2*** |
Data are represented as mean ± SEM. ## P < 0.01, ### P < 0.001 compared with WT group (n = 6–10 per group).
*P < 0.05. **P < 0.01. ***P < 0.001 compared with ApoE−/− group (treated with vehicle control).